The National Institute for Allergy and Infectious Diseases (NIAID) has awarded contracts worth $56.1 million to four companies for advanced development of anthrax antitoxins, as well as therapeutics and antibiotics for use against plague and tularemia. The largest award, $20.7 million, went to Nanotherapeutics, Inc., to advance the development of a new approach to formulate an existing antibiotic called Gentamicin so that it can be inhaled for outpatient use. Gentamicin currently can only be administered intravenously in a hospital. The…
Recommended
Trending
Congress Updates
In Response To Flag Concerns, DoD Looks To Reduce Drone Prices, As Order for 30,000 Looms
The Pentagon is bargain shopping for Group 1 drones, as other countries, including Ukraine and China, have taken advantage of consumer electronics-level prices to bolster their stables. “In last spring’s […]
Amid Questions On Weapons Stockpiles, Caine Says U.S. Has ‘Sufficient’ Munitions For Iran Operation
Pentagon leaders on Wednesday sought to quell concerns over the rate at which the U.S. is employing critical munitions in its military strike campaign against Iran, with lawmakers also pressing […]
SASC Leaders Criticize Trump’s Defense Strategy, Press Colby On Policy Shifts
Senate Armed Services Committee (SASC) leadership on Tuesday criticized the Trump administration’s new National Defense Strategy (NDS) and pressed the Pentagon’s top policy official to explain the document’s priorities. SASC […]
Wicker Wants Legislation On DoD’s Equity Investments In Minerals Supply Chain
Legislation regarding equity investments by the Defense Department in critical mineral supply chains is needed to strengthen the larger defense industrial base and demonstrate to the “free market” that the […]